Hamilton A, Volm M
Kaplan Comprehensive Cancer Center, New York University, School of Medicine, New York 10016, USA.
Oncology (Williston Park). 2001 Aug;15(8):965-72; discussion 972, 977-9.
Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer. This article will review the role of aromatase in the pathogenesis of breast cancer and the results of recent studies that have established the role of its inhibitors in estrogen-receptor-positive breast cancer. We will also briefly outline the rationale and design of ongoing studies.
阿那曲唑（瑞宁得）、来曲唑（弗隆）和依西美坦（阿诺新）是第三代芳香化酶抑制剂，现已取代氨鲁米特（氨苯哌酮）、孕激素和他莫昔芬（诺瓦得士），成为雌激素受体阳性、绝经后转移性乳腺癌的首选激素治疗药物。本文将综述芳香化酶在乳腺癌发病机制中的作用，以及近期研究确定其抑制剂在雌激素受体阳性乳腺癌中作用的结果。我们还将简要概述正在进行的研究的基本原理和设计。
